Neuropsychiatric symptoms and the outcome of cognitive trajectories in older adults free of dementia: The Mayo Clinic Study of Aging by Krell‐Roesch, Janina et al.
Received: 25 November 2020 - Revised: 11 February 2021 - Accepted: 26 February 2021DOI: 10.1002/gps.5528
R E S E A RCH AR T I C L E
Neuropsychiatric symptoms and the outcome of cognitive
trajectories in older adults free of dementia: The Mayo Clinic
Study of Aging
Janina Krell‐Roesch1,2 | Jeremy A. Syrjanen1 | Mary M. Machulda3 |
Teresa J. Christianson1 | Walter K. Kremers1 | Michelle M. Mielke1,4 |
David S. Knopman4 | Ronald C. Petersen1,4 | Maria Vassilaki1 | Yonas E. Geda5
1Department of Quantitative Health Sciences,
Mayo Clinic, Rochester, Minnesota, USA
2Institute of Sports and Sports Science,
Karlsruhe Institute of Technology, Karlsruhe,
Germany
3Department of Psychiatry and Psychology,
Mayo Clinic, Rochester, Minnesota, USA
4Department of Neurology, Mayo Clinic,
Rochester, Minnesota, USA
5Department of Neurology, Barrow
Neurological Institute, Phoenix, Arizona, USA
Correspondence
Yonas E. Geda, Alzheimer's Disease and
Memory Disorders Program. Department of
Neurology, Barrow Neurological Institute,




Support for this research was provided by NIH
grants: National Institute on Aging (R01
AG057708; U01 AG006786; P50 AG016574;
R01 AG034676), and National Institute of
Mental Health (K01 MH068351). This project
was also supported by the Robert Wood
Johnson Foundation, the Robert H. and Clarice
Smith and Abigail Van Buren Alzheimer's
Disease Research Program, the GHR
Foundation, the Mayo Foundation for Medical
Education and Research, the Edli Foundation
and Alzheimer's Barrow Neurological
Institute.
Abstract
Objective: Neuropsychiatric symptoms (NPS) are associated with the risk of inci-
dent mild cognitive impairment (MCI) and dementia. We examined associations
between NPS and the outcomes of global and domain‐specific cognitive trajectories.
Methods: In this longitudinal study conducted in the setting of the population‐based
MayoClinic StudyofAging, 5081community‐dwelling, nondemented individuals aged
≥50 years (51%males) underwentNPS assessment usingNeuropsychiatric Inventory
Questionnaire (NPI‐Q), and Beck Depression and Anxiety Inventories (BDI‐II, BAI).
Global and domain‐specific (memory, language, attention, and visuospatial skills)
cognitive performance was assessed through neuropsychological testing every 15
months. Associations between baseline NPS and trajectories for individual yearly
change in cognitive z‐scores were calculated using linear mixed‐effect models.
Results: Cognition declined regardless of NPS status over the median follow‐up of
4.5 years. Presence of NPS was associated with increased cognitive decline. Dif-
ferences in annualized change in global cognition z‐scores for participants with NPS
compared to without NPS ranged from −0.018 (95% CI −0.032, −0.004; p = 0.011)
for irritability to −0.159 (−0.254, −0.065; p = 0.001) for hallucinations. Associations
between NPS and annual decline in global cognition were significant for most NPI‐
Q‐assessed NPS and clinical depression (BDI‐II≥13). Participants with NPI‐Q‐
assessed depression, apathy, nighttime behavior, and clinical depression had
greater decline in all domain‐specific z‐scores; presence of delusions and anxiety
was associated with more pronounced decline in language, attention and visuo-
spatial skills.
Conclusion: NPS were associated with a more accelerated cognitive decline. Clinical
assessment and potential treatment of NPS is warranted even in a community
setting as NPS may impact cognitive decline in nondemented individuals.
This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any
medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
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Key points
� Presence of neuropsychiatric symptoms was associated with a more accelerated global and
domain‐specific cognitive decline
� Participants with depression or apathy had greater decline in all domain‐specific z‐scores
� Presence of delusions and anxiety was associated with more pronounced decline in lan-
guage, attention and visuospatial skills
� Clinical assessment and potential treatment of neuropsychiatric symptoms is warranted
even in a community setting
1 | INTRODUCTION
Neuropsychiatric symptoms (NPS) such as depression or apathy are
very common in older adults with or without cognitive impairment.1–8
Furthermore, prospective studies have shown that NPS are risk fac-
tors for new onset of categorical outcomes of mild cognitive impair-
ment (MCI)9–11 or dementia.12–16
However, little is known about the population‐based associations
between various NPS and cognitive trajectories in older adults free of
dementia. For example, a recent analysis derived from the Cache
County study showed that overall NPS burden among clinically
normal older adults was associated with a more rapid cognitive
decline over 5.7 years of follow‐up, but results for individual NPS
(e.g., depression or anxiety) and their respective associations with
cognitive decline were conflicting.17
Therefore, the aim of this study was to examine the longitudinal
associations between self‐as well as informant‐reported NPS and
longitudinal trajectories of cognitive performance in a sample of
nondemented community‐dwelling older individuals aged ≥50 years.
We hypothesized that baseline NPS, be it self‐reported or informant‐
observed, would be associated with a more accelerated decline in
global and domain‐specific cognitive performances over time.
2 | METHODS
2.1 | Setting and study sample
The study was conducted in the setting of the population‐based
Mayo Clinic Study of Aging (MCSA) in Olmsted County, MN, USA.
We included persons aged ≥50 years who were either cognitively
unimpaired (CU) or had MCI, and on whom self‐ and informant‐based
information on NPS at baseline as well as cognitive performance
measurements were available. Neuropsychological testing was con-
ducted approximately every 15 months. MCSA study protocols have
been approved by the IRB of the Mayo Clinic and Olmsted Medical
Center in Rochester, MN. All participants provided written informed
consent.
2.2 | Cognitive evaluation
The MCSA study protocol is described in detail elsewhere.18 Briefly,
all participants underwent a face‐to‐face evaluation including a
neurological examination performed by a physician, a risk factor
ascertainment conducted by a study coordinator, and standardized
neuropsychological testing which was administered by a psycho-
metrist supervised by a board‐certified neuropsychologist, in order to
assess performance in four cognitive domains: (1) memory (delayed
recall trials from Auditory Verbal Learning Test,19 Wechsler Memory
Scale‐Revised,20 Logical Memory and Visual Reproduction subtests);
(2) attention/executive function (Trail‐Making Test Part B,21
Wechsler Adult Intelligent Scale‐Revised,22 Digit Symbol Substitution
subtest); (3) language (Boston Naming Test,23 category fluency);24
and (4) visuospatial skills (Wechsler Adult Intelligence Scale‐
Revised,22 Picture Completion and Block Design subtests). An
expert consensus panel consisting of physicians, study coordinators,
and neuropsychologists reviewed the results for each participant and
determined whether a participant was CU or had MCI. Individuals
were classified as CU based on normative data developed on a
different sample in this community.25–28 For MCI, the Mayo Clinic
criteria for MCI29,30 were used: (1) cognitive concern expressed by a
physician, informant, participant, or study coordinator; (2) impair-
ment in one or more cognitive domains (memory, attention/executive
function, language, or visuospatial skills); (3) essentially normal
functional activities; and (4) absence of dementia. Participants with
MCI had a Clinical Dementia Rating (CDR) score of 0 or 0.5; however,
the final diagnosis of MCI was based on all available data.
2.3 | Measurement of neuropsychiatric symptoms
NPS were assessed using the Neuropsychiatric Inventory Question-
naire (NPI‐Q;31), the Beck Depression Inventory (BDI‐II;32), and the
Beck Anxiety Inventory (BAI;33). The NPI‐Q was administered as a
structured interview to an informant by a study coordinator and
assessed the presence/absence of twelve emotional behaviors
(i.e., depression, anxiety, apathy, agitation, delusions, hallucinations,
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euphoria, disinhibition, irritability, aberrant motor behavior, night-
time behavior/sleep, and eating/appetite). The BDI‐II and BAI are
validated, self‐administered inventories. The BDI‐II is a 21‐item
questionnaire that measures symptoms of depression over the last
two weeks, such as feeling guilty and loss of interest. Similarly, the
BAI is a 21‐item questionnaire that assesses symptoms of anxiety
such as nervousness and fear of losing control over the last seven
days. The severity of each symptom in both BDI‐II and BAI is rated on
a scale ranging from 0 (low severity) to 3 (high severity). The total
score for both inventories thus ranges from 0 to 63, with a higher
score indicating a higher severity of depressive and anxiety symp-
toms, respectively.
2.4 | Measurement of neuropsychological test
scores
From all neuropsychological tests described under “cognitive evalu-
ation,” we used continuous measures that were not age normed.
Longitudinal z‐scores were calculated relative to the baseline scores
by converting individual test scores to z‐scores. We then created
domain‐specific z‐scores by z‐scoring the averages of the test‐
specific z‐scores and also created a global z‐score by z‐scoring the
averages of the domain‐specific z‐scores. The outcome of interest for
the linear mixed‐effect model analyses was the longitudinal change in
cognitive measures of memory, attention/executive function, lan-
guage, visuospatial skills, and global cognition.
2.5 | Statistical analysis
We calculated linear mixed‐effect models with random subject‐
specific intercepts and slopes to examine the longitudinal associa-
tion between NPS at baseline and change in cognitive z‐scores over
time. In our models, NPS at baseline were the independent variables
(predictors), and the trajectories for individual yearly change in
cognitive z‐scores over time were the dependent variables (out-
comes). All models included NPS at baseline, time in years from
baseline and their interaction. We conducted the analyses for twelve
NPS as assessed by the NPI‐Q, and also included clinical depression
(BDI‐II score ≥ 13) and clinical anxiety (BAI score ≥ 10) in the
models. All models were adjusted for age, sex, education, and
whether or not the participant had previously taken the cognitive
tests. All statistical analyses were done using the conventional two‐
tailed alpha level of 0.05 and performed with SAS 9.4 (SAS Insti-
tute, Inc).
3 | RESULTS
The sample consisted of 5081 persons (2612 males, 51.4%) of whom
4439 persons (87.4%) were CU and 642 (12.6%) had MCI. The me-
dian (interquartile range, IQR) age was 74.4 (67.4, 81.2) years, the
median (IQR) years of education were 14.0 (12.0, 16.0), and median
(IQR) follow‐up time was 4.5 (1.3, 6.8) years. Participant de-
mographics at baseline are displayed in Table 1.
Longitudinal analyses revealed statistically significant associa-
tions between NPS at baseline and change in global cognitive z‐
score over time (Figure 1, Table A1). For apathy as an example,
the coefficient for time indicates that each one year increase in
time is associated with a decline in global z‐score of 0.071 for
participants without apathy. Whereas participants with apathy
showed a decline in global cognitive z‐score of 0.128 (i.e.,
−0.071 + (−0.057)); thus, persons with apathy have an increased
degree of global cognitive decline than persons without apathy. The
interaction between time since baseline and NPS was statistically
significant for delusions, hallucinations, agitation, depression, anxi-
ety, apathy, irritability, motor behavior, nighttime behavior, appetite
change (all assessed using NPI‐Q) as well as clinical depression (BDI
score ≥ 13; Figure 1, Table A1). The coefficients for the variables
we adjusted for ranged, depending on the different NPS, between
−0.055 and −0.056 for age, −0.196 and −0.217 for sex, 0.109 and
0.112 for education, and −0.204 and −0.206 for whether or not the
participant had previously taken the cognitive tests (data not
shown).
Similarly, NPI‐Q‐assessed hallucinations, agitation, depression,
apathy, irritability, motor behavior, nighttime behavior and appetite
change as well as clinical depression were statistically significantly
associated with declining memory z‐scores over time (Figure 2,
Table A2). With regard to attention, the interactions were statisti-
cally significant for NPI‐Q‐assessed delusions, hallucinations,
depression, anxiety, apathy, irritability, motor behavior, nighttime
behavior, and appetite change as well as clinical depression (Figure 2,
Table A3). Additionally, delusions, agitation, depression, anxiety,
apathy, nighttime behavior and appetite change as assessed by the
NPI‐Q as well as clinical depression were statistically significantly
associated with a decline in language (Figure 2, Table A4). Finally,
delusions, depression, anxiety, apathy and nighttime behavior as well
as clinical depression were significantly associated with decline in
visuospatial skills (Figure 2, Table A5).
4 | DISCUSSION
Here we report the association between NPS at baseline and longi-
tudinal decline in cognitive performance in a population‐based sam-
ple of CU individuals and persons with MCI over a median follow‐up
of 4.5 years. As hypothesized, presence of informant‐reported NPS
as assessed by the NPI‐Q, particularly depression, apathy and
nighttime behavior, were associated with statistically significant
decline in performance of all four cognitive domains as well as global
cognition. In addition, clinical depression, as indicated by a BDI‐II
score ≥13, was also associated with significant decline in domain‐
specific and global cognition, whereas no significant associations
were observed for clinical anxiety as indicated by a BAI score ≥10
and changes in cognitive function over time.
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In the past, several studies have examined the associations be-
tween NPS and incidence of MCI9–11 and dementia.12–16 A relatively
smaller number of longitudinal studies have investigated associations
between NPS and cognitive trajectories as a continuous measure, and
most of these studies focused on depression34–36 or anxiety.37,38 For
example, in a large sample of over 4000 adults aged ≥65 years,
TAB L E 1 Participant characteristics
at baseline
Variable CU (N = 4439) MCI (N = 642) Total (N = 5081)
Age, years 73.7 (66.2, 80.3) 80.6 (73.9, 84.4) 74.4 (67.4, 81.2)
Male sex 2243 (50.5) 369 (57.5) 2612 (51.4)
Education, years 14.0 (12.0, 16.0) 12.0 (12.0, 15.0) 14.0 (12.0, 16.0)
Race/ethnicity
White 4371 (98.5) 629 (98.0) 5000 (98.4)
Asian 22 (0.5) 4 (0.6) 26 (0.5)
Black 11 (0.2) 1 (0.2) 12 (0.2)
Othera 35 (0.8) 8 (1.2) 43 (0.9)
Delusions 13 (0.3) 18 (2.8) 31 (0.6)
Hallucinations 7 (0.2) 6 (0.9) 13 (0.3)
Agitation 113 (2.5) 55 (8.6) 168 (3.3)
Depression 470 (10.6) 167 (26.0) 637 (12.5)
Anxiety 249 (5.6) 91 (14.2) 340 (6.7)
Euphoria 19 (0.4) 12 (1.9) 31 (0.6)
Apathy 183 (4.1) 111 (17.3) 294 (5.8)
Disinhibition 53 (1.2) 29 (4.5) 82 (1.6)
Irritability 336 (7.6) 128 (19.9) 464 (9.1)
Motor behavior 28 (0.6) 11 (1.7) 39 (0.8)
Nighttime behaviorb 277 (7.3) 98 (18.2) 375 (8.7)
Appetite 191 (4.3) 60 (9.3) 251 (4.9)
BDI‐II score ≥ 13c 279 (6.4) 99 (15.9) 378 (7.6)
BAI score ≥ 10d 277 (6.3) 87 (13.6) 364 (7.2)
z‐score memorye 0.20 (−0.46, 0.84) −1.41 (−1.88, −0.84) 0.04 (−0.72, 0.74)
z‐score attentionf 0.22 (−0.35, 0.76) −1.12 (−2.12, −0.32) 0.12 (−0.54, 0.68)
z‐score languageg 0.18 (−0.38, 0.73) −0.98 (−1.80, −0.37) 0.07 (−0.55, 0.67)
z‐score visuospatialh 0.18 (−0.47, 0.80) −0.99 (−1.64, −0.34) 0.07 (−0.65, 0.71)
z‐score global cognitioni 0.23 (−0.38, 0.80) −1.39 (−1.93, −0.88) 0.08 (−0.62, 0.70)
Note: Continuous variables are presented as median (IQR) and categorical variables are presented as
N (%).
Abbreviations: BAI, Beck Anxiety Inventory; BDI‐II, Beck Depression Inventory‐II; CU, cognitively
unimpaired; IQR, interquartile range; MCI, mild cognitive impairment; NPS, neuropsychiatric
symptoms.
aOther includes: American Indian/Alaska Native (N = 3), more than one race (N = 25), unknown race
(N = 15).
bInformation missing on 751 participants (646 CU, 105 MCI).
cInformation missing on 92 participants (71 CU, 21 MCI).
dInformation missing on 12 participants (8 CU, 4 MCI).
eInformation missing on 69 participants (54 CU, 15 MCI).
fInformation missing on 208 participants (155 CU, 53 MCI).
gInformation missing on 164 participants (130 CU, 34 MCI).
hInformation missing on 221 participants (170 CU, 51 MCI).
iInformation missing on 328 participants (248 CU, 80 MCI).
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depressive symptoms were significantly associated with a decline in
global cognitive function over 3 years, and this association existed
even when restricting the analysis to participants who were CU at
baseline.39 Similarly, researchers from Australia found that mild
worry and depressive symptoms were associated with decline in vi-
sual learning and memory at 2‐year follow‐up in community‐dwelling
older adults.40 Investigators from the Netherlands reported that
anxiety symptoms were associated with stronger decline in verbal
memory in nondemented individuals aged ≥65 years.41
To date, few studies have examined other NPS except depression
and anxiety, for example, a study from the United Kingdom reported
that older, nondemented adults with psychotic symptoms experi-
enced a more pronounced decline in non‐memory cognitive functions
than individuals without psychotic symptoms after 6 years of follow‐
up.42 Furthermore, a study in more than 9000 CU older adults
showed that those individuals with mild behavioral impairment (MBI)
experienced greater decline in attention and working memory per-
formance after one year as compared to persons without MBI.43
Researchers from Australia conducted a study among 873
community‐dwelling older adults and reported that anxiety was
associated with decline in executive function, and that agitation was
associated with decline in language over two years of follow‐up.44
Finally, a recently published research derived from the Cache County
study among 470 older adults showed that higher NPS burden as
assessed by the Neuropsychiatric Inventory total score at baseline
was associated with more pronounced decline on word list memory
and recall, delayed praxis recall, and animal fluency tasks.17 However,
in contrast to our findings, depression was not associated with
decline in any cognitive outcome measure, whereas anxiety was
associated with more rapid decline in the symbol digit modalities
test.17 The differences in results between their study and ours may
be due to different samples and different assessment tools for NPS
and cognitive function.
Overall, our study expands on the existing body of literature by
providing evidence of an association between various self‐ and
informant‐reported NPS, particularly depression, apathy and night-
time behavior, with domain‐specific and global cognitive trajectories
in a population‐based sample of more than 5000 older adults. While
it is expected, based on previous research, to observe associations
between various NPS with memory and attention/executive func-
tion,44 the associations between NPS with language and visuospatial
skills are less established. Indeed, we found that 10 NPI‐Q‐assessed
NPS and clinical depression were associated with increased longitu-
dinal decline in global cognition, eight NPI‐Q‐assessed NPS and
clinical depression with increased decline in memory, and nine NPI‐
Q‐assessed NPS and clinical depression with increased decline in
attention/executive function. In contrast, only seven NPI‐Q‐assessed
NPS and clinical depression were associated with increased longitu-
dinal decline in language and five NPI‐Q‐assessed NPS and clinical
depression with increased decline in visuospatial skills. More
research is needed to confirm the observations by our group and
others, particularly with regard to the conflicting findings on the
associations between depression and anxiety with cognitive decline.
In addition, it would also be interesting to examine potential asso-
ciations between current NPI‐Q or 1‐lagged NPI‐Q with cognitive
trajectories, as it is known from literature that NPI‐Q trajectories are
quite variable and unlike cognition do not proceed in a straight line in
a single direction. Furthermore, it may be useful to also consider NPI‐
Q domain scores or NPI‐Q total score in addition to the dichotomized
NPI‐Q domain scores as in our current research.
Our study did not examine potential mechanisms that may un-
derlie an association between NPS and cognitive decline over time.
However, previous research has suggested that depressive symptoms
may moderate cognitive decline associated with changes in brain
white matter hyperintensities.45 With regard to an association be-
tween anxiety and cognitive decline, potential explanations may
F I GUR E 1 Longitudinal association between presence of Neuropsychiatric symptoms at baseline (IV) and change in global cognition z‐
score over time (DV)
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include hypercortisolism, low‐grade inflammation, and increased
levels of cytokines, or suppression of neurotrophic factors such as
brain‐derived neurotrophic factor (BDNF).46
The strengths of our study are the large sample size of
community‐dwelling individuals free of dementia and the rigorous
assessment of both informant‐based and self‐reported NPS using
three validated instruments. This enabled us to not only focus on
depression and anxiety as done in many previous studies but also to
look at potential associations between other NPS such as apathy,
agitation or nighttime behavior with cognitive trajectories. One
weakness of our study pertains to its observational nature. Such a
design limits etiologic inference that one can make despite the lon-
gitudinal nature of our study. Furthermore, as we have consistently
observed6,9 and as expected, the frequency and distribution of NPS,
particularly psychotic symptoms such as delusions or hallucinations,
is very low in a population‐based sample. Therefore, one needs to be
cautious in generalizing our findings to samples derived from
behavioral neurology and neuropsychiatry clinics where the preva-
lence of NPS including clinically significant NPS is considerably
higher. Nevertheless, our study findings can be particularly infor-
mative to policy makers and stakeholders that make recommenda-
tions based on NPS events that occur in a community setting.
In addition, we did not adjust our analyses for multiple comparisons
which may increase Type I error. However, when considering a
Bonferroni correction for our analyses, the alpha significance level
would be 0.004 (i.e., 0.05/14 since we have a total of 14 predictor
variables). Thus, when taking Table A1 as an example, nine out of the
11 significant p values for the interaction between NPS and change in
cognitive z‐scores would still remain significant and none of our
major conclusions would be affected by the correction. Finally, when
F I GUR E 2 Longitudinal association between presence of Neuropsychiatric symptoms at baseline (IV) and change in domain‐specific
cognitive z‐score over time (DV)
6 - KRELL‐ROESCH ET AL.
interpreting our results, one needs to keep in mind that statistical
significance, particularly given our large sample size, not always
translates to clinical significance. Thus, the observed differences in
annualized changes in global or domain‐specific cognition z‐scores
for participants with compared to without given NPS over a span
of 4.5 years may not always be clinically meaningful. However, when
taking NPI‐Q‐assessed depression predicting memory change as an
example (Table A2), it can be seen that the time coefficient is −0.039
and having depression adds on −0.026 (time� depression interaction
coefficient). Thus, having depression almost doubles memory decline
over time. An alternative way of interpretation would be to compare
to the age coefficient which is −0.049 (data not shown), that is,
having depression is comparable to adding about half a year in age
extra with each passing year.
In conclusion, our study adds to the growing body of research
providing evidence of an association between NPS with longitudinal
cognitive decline in community‐dwelling older adults free of de-
mentia. Particularly, presence of depression, apathy, and nighttime
behavior at baseline was associated with more pronounced decline in
performance in all cognitive domains (i.e., memory, attention, lan-
guage, and visuospatial function) as well as global cognition.
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